Rigel Pharmaceuticals (RIGL) risk factors, FY2024 10-K

Risks Related to Our Business and Our Industry

1. 01If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer
2. 02We may need to continue to increase the size of our organization and we may encounter difficulties with managing our growth, which could adversely affect our business and results of operations
3. 03Our strategy to expand our hematology and oncology pipeline on our own, or through acquisitions or in-licensing of early or late-stage products or companies, or through partnerships with pharmaceutical and biotechnology companies, as well as academic institutions and government organizations, may not be successful
4. 04There is a high risk that drug discovery and development efforts might not generate successful product candidates
5. 05programs may require additional investment in resources, and could impact availability of previously useful data
6. 06The UK to date has not adopted dedicated AI legislation, instead looking to rely on a principles-based, sector-specific approach to AI regulation. However, in July 2024 it was announced that new AI regulation would in fact be introduced
7. 07Significant changes or developments in US laws or policies, including changes in US healthcare regulation, may have a material adverse effect on our business
8. 08The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
9. 09If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed
10. 10The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner’s patents. If this were to occur with respect to our products or products with which it competes, our business would be harmed
11. 11Discovery of unforeseen safety problems or increased focus on a known problem could impact our ability to commercialize our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market
12. 12in regulatory review resulting from such disruptions could materially affect the completion of our clinical trials
13. 13our rebate agreement, no federal payments would be available under Medicaid for our covered outpatient drugs or under Medicare Part B for any of our products that may be reimbursed under Part B
14. 14We will need additional capital in the future to sufficiently fund our operations and research
15. 15We rely and may continue to rely on two distribution facilities for the sale of our products and potential sale of any of our product candidates
16. 16Forecasting potential sales for any of our product candidates will be difficult, and if our projections are inaccurate, our business may be harmed, and our stock price may be adversely affected
17. 17We do not and will not have access to all information regarding our products and product candidates we licensed to our collaboration partners
18. 18Our future funding requirements will depend on many uncertain factors
19. 19Our success as a company is uncertain due to our history of operating losses and the uncertainty of any future profitability
20. 20If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed
21. 21If conflicts arise between our collaborators or advisors and us, any of them may act in their self-interest, which may be adverse to our stockholders’ interests
22. 22Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain
23. 23Additional uncertainty may result because no consistent policy regarding the breadth of legal claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in our or other companies’ patents
24. 24If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities
25. 25Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
26. 26Our ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited
27. 27Changes in valuation allowance of deferred tax assets may affect our future operating results
28. 28Because we expect to be dependent upon collaborative and license agreements, we might not meet our strategic objectives
29. 29Securities class action lawsuits or other litigation could result in substantial damages and may divert management’s time and attention from our business
30. 30If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated
31. 31Accordingly, our competitors may succeed in obtaining patent protection, identifying or validating new targets or developing new drug compounds before we do
32. 32Our stock price may be volatile, and our stockholders’ investment in our common stock could decline in value
33. 33We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect
34. 34If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
35. 35We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts
36. 36into consulting arrangements with competing pharmaceutical or biotechnology companies, any of which may have a detrimental impact on our research objectives and could have an adverse effect on our business, financial condition and results of operations
37. 37If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages, penalties or fines
38. 38Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches
39. 39Future equity issuances or a sale of a substantial number of shares of our common stock may cause the price of our common stock to decline

Risks Related to Clinical Development and Regulatory Approval

1. 40Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
2. 41the Center for Medicare Innovation at CMS announced a new model, the Enhancing Oncology Model, that is designed to make high-quality cancer care more affordable to both patients and Medicare
3. 42See “Part I, Item 1 – Business – Government Regulation – Healthcare Reform” of this Annual Report on Form 10-K, for additional information
4. 43Delays in clinical testing could result in increased costs to us
5. 44our other clinical programs. If we are unable to enroll the patients in these trials at the projected rate, the completion of the clinical program could be delayed and the costs of conducting the program could increase, either of which could harm our business
6. 45Negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop, or of other products similar to products we are developing, could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals
7. 46If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the marketing and sales of our products could be delayed and we may be subject to enforcement action, which could decrease our revenues
8. 47If we are unable to obtain regulatory approval to market products in the US and foreign jurisdictions, we will not be permitted to commercialize products we or our collaborative partners may develop

Risks Related to Commercialization

1. 48Our prospects are highly dependent on our commercial products. To the extent that the commercial success of our products in the US is diminished or is not commercially successful, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline
2. 49If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed
3. 50We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and approval process
4. 51Commercialization of our product candidates depends upon successful completion of extensive preclinical studies and clinical trials to demonstrate their safety and efficacy for humans. Preclinical testing and clinical development are long, expensive and uncertain processes
5. 52Global economic conditions could adversely impact our business
6. 53Bank failures or other events affecting financial institutions could adversely impact our liquidity and other business
7. 54Shareholder activism and private securities-related litigation could cause material disruption to our business
8. 55Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult
9. 56In addition, Section 203 of the Delaware General Corporation Law (DGCL), which imposes certain restrictions relating to transactions with major stockholders, may discourage, delay or prevent a third party from acquiring us
10. 57Increasing use of social media could give rise to liability and may harm our business
11. 58Our future success depends on our ability to attract and retain key employees and relationships
12. 59Our facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations